stockrowBeam Therapeutics Inc.
BEAM Healthcare Biotechnology
Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −16.7%
- Free cash flow
- −29.5%
Quarter to September 2026, against a year earlier
Follow BEAM
Alert me
Beam Therapeutics Inc. (BEAM) Revenue growth
Beam Therapeutics Inc.'s revenue growth over the twelve months to 30 September 2026 was 163.3%, up 43.3 percentage points from fiscal 2025 (120.0%). Over the past ten years it has ranged from −83.2% (fiscal 2024) to 215,916.7% (fiscal 2021); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 6.26% and above the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 120.0% | 203.19 |
| FY2024 | −83.2% | (603.19) |
| FY2023 | 520.0% | 502.50 |
| FY2022 | 17.5% | (215,899.16) |
| FY2021 | 215,916.7% | 215,883.34 |
| FY2020 | 33.3% | 58.33 |
| FY2019 | −25.0% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | −96.8% | (2.62) |
| Jun 2026 | −94.2% | (419.08) |
| Mar 2026 | 324.9% | 45.35 |
| Dec 2025 | 279.5% | 311.55 |
| 26 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| BEAM Beam Therapeutics Inc. | 163.3% |
| ZLAB Zai Lab Limited Unsponsored ADR compare | 0.02% |
| NAMS NewAmsterdam Pharma Company N.V. compare | −26.4% |
| XNCR Xencor, Inc. compare | −28.6% |
| RCUS Arcus Biosciences, Inc. compare | −58.3% |
| VRDN Viridian Therapeutics, Inc. compare | −62.8% |
| IDYA IDEAYA Biosciences, Inc. compare | −83.6% |
| TLX Telix Pharmaceuticals Limited compare | — |
| MBX MBX Biosciences, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on BEAM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- The full statement